Connect with us


Biopharma executives applaud the Supreme Court for backing the FDA in abortion case




Biopharma executives applaud the Supreme Court for backing the FDA in abortion case

OOn Thursday, the Supreme Court rejected an attempt by anti-abortion doctors to ban the shipment of the abortion pill mifepristone. The case posed a serious challenge to the Food and Drug Administration’s authority to regulate drugs.

Biopharmaceutical companies and physician organizations applauded the ruling, but also warned that threats to access to mifepristone are far from over.

Daphne Zohar, CEO of Seaport Therapeutics:

“Today’s decision ensures that patients and drug developers can rely on the FDA’s rigorous approval process as the scientific and trusted standard for drug approvals. Regulatory certainty is critical to ensuring that new drugs can reach the laboratory bench to a patient’s bedside.

Jim Stansel, general counsel of industry group PhRMA:

“We are pleased with today’s decision from the U.S. Supreme Court, which provides innovative biopharmaceutical companies with the certainty needed to bring future medicines to patients.”

Evan Masingill, CEO of generic mifepristone maker GenBioPro:

“While the Supreme Court’s ruling upholds access to mifepristone for medical abortions, the threat to the established FDA approval of mifepristone and the FDA’s regulatory authority remains. We know that politically motivated attacks by extremists against mifepristone will not end here.”

Jeremy Levin, CEO of Ovid Therapeutics:

“[There] is not a victory in a war that should never have been fought. The mifepristone case…was an attempt to suppress women’s health and rights and overthrow the very foundation of the system that drives innovation. However, we must be vigilant, these radicals will continue their efforts to overthrow women’s rights and innovation in the US.”

John Maraganore, former biotech executive and investor:

“This is a huge victory for the FDA and its authorities, for science and the importance of evidence over religious beliefs, and for women and their rights. Thank God!”

Bobby Mukkamala, president-elect of the American Medical Association:

“Attempts to question the FDA’s scientific judgment and roll back access to mifepristone were based on a sham case that not only lacked standing, but also relied on speculative accusations and ideological claims to undermine decades of rigorous scientific review. ..substantial evidence shows that restricting access to mifepristone essential abortion care without justification has a psychological, physical and economic toll.”